Phosphatidylinositol increases HDL-C levels in humans

Abstract

Studies have shown that phosphatidylinositol (PI) can stimulate reverse cholesterol transport by enhancing the flux of cholesterol into HDL and by promoting the transport of high density lipoprotein-cholesterol (HDL-C) to the liver and bile. The goal of this study was to determine the safety and therapeutic value of PI after oral administration to normolipidemic human subjects. We performed a randomized 2 week study in 16 normolipidemic subjects. Subjects received either 2.8 or 5.6 g of PI, with or without food. PI was well tolerated by all subjects. PI significantly affected the levels of HDL-C and triglyceride in the plasma of subjects receiving PI with food. The lower dose showed a 13% increase in HDL-C, whereas the high dose showed an increase of 18% over the 2 week period. Both low-and highdose groups showed significant increases in plasma apolipoprotein A-I. The high dose of PI also decreased plasma triglycerides by 36% in the fed subjects. These data suggest that after only 2 weeks, PI may have a comparable therapeutic value to niacin, with negligible side effects.

Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport

“…114 In a small clinical trial, 2 weeks of treatment with oral phosphatidylinositol resulted in a significant increase of 13% to 18% in HDL-C levels. 115 Another group reported that oral administration of the phospholipid 1,2-dimyristoyl-sn-glycero-3-phosphocholine to apoE-null mice led to an increase in HDL-C levels and HDL function and a reduction in atherosclerosis. 116 One appeal of phospholipids as therapeutic agents is that they are natural substances and would be expected to have a good safety profile.…”

Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia

“…Intravenous administration of PI has also been shown to inhibit lecithin-cholesterol acyltransferase (LCAT) and cholesterylester transfer protein (CETP), two important enzymes involved in cholesterol metabolism (36,37). Inhibition of these enzymes by anionic phospholipids results in the inhibition of production, transfer and storage of cholesterol in the apoB-containing lipoprotein pool (32,38). Anionic phospholipids such as PI and PG may also regulate triglyceride metabolism by stimulation of triglyceride lipases including hepatic-, lipoprotein-and pancreatic lipase.…”

Influence of glucogenic dietary supplementation and reproductive state of dairy cows on the composition of lipids in milk

“…Polar lipids are considered health-promoting bioactive constituents in the human diet due to their effect on plasma lipid profile, colon cancer pathogenesis and even gut bacteria population (Dillehay et al, 1994;Burgess et al, 2005). The concentrations of polar lipids in milk also have industrial implications due to their emulsifying properties, which are required for some food systems (Thompson and Singh, 2006).…”